Aptevo Therapeutics Presents Key Features of ADAPTIR

Aptevo Therapeutics (NASDAQ:APVO) revealed new information of its ADAPTIR protein therapeutic platform at two medical conferences.
As quoted in the press release:

In a presentation entitled, “From the Bench to the Clinic: Developing Next Generation ADAPTIR molecules,” Dr. David Bienvenue, Senior Director, Protein Sciences, presented an overview of the key differentiating features of Aptevo’s ADAPTIR technology.  The presentation highlighted the activity, stability and manufacturability of ADAPTIR bispecifics and included recent data for a lead preclinical candidate, APVO436, which targets CD123 and CD3.  APVO436 has shown potent biological activity in preclinical studies and is advancing towards first-in-human clinical trials.

“Aptevo’s ADAPTIR therapeutic protein platform offers important advantages over other bispecific antibody formats,” remarked Dr. Bienvenue.  “First, the flexible and modular nature of the ADAPTIR structure provides the ability to engineer protein therapeutics that can engage the immune system through diverse mechanisms of action, including redirected T-cell cytotoxicity, targeted cytokine delivery and receptor blockade, among others.  Second, the unique homodimeric structure enables the easy assembly and screening of new drug candidates, while avoiding the pitfalls encountered with heterodimeric bispecific formats.  Recent improvements to the ADAPTIR scaffold and screening processes have led to candidates with increased expression levels, stability, and improved serum half-life (up to 12.5 days in rodents), while retaining traditional antibody-like manufacturing characteristics. These enhanced features enable the design and development of custom-engineered protein therapeutics with novel mechanisms of action and highly favorable supply economics.  We believe this optimally positions our ADAPTIR candidates vis-à-vis other immunotherapy strategies.”

Click here to read the full press release.

Source: globenewswire.com